The world’s first smart needle is the result of more than 15 years of R&D

Imagine if doctors had a needle that could precisely identify when the tip reaches the right spot? That is the vision that sparked Injeq’s groundbreaking development work, the result of which is the first smart needle of its kind in the world.

The smart needle has been developed since 2003 by Injeq’s interdisciplinary team that combines solid medical and technological expertise. Katja Paassilta (DDS, MSc Eng), Riitta Seppänen-Kaijansinkko (MD, DDS, PhD, Prof) and Jari Hyttinen (DSc Tech, Prof), along with their teams, have carried out pioneering work to develop the bioimpedance-based measurement technology.

The very first prototype of the device was made using a commercial hypodermic needle and components purchased from an electronics store. Paassilta performed the first test punctures in her home, on gel tissue she made from gelatin.

Now, two decades later, the smart needle and the measurement unit connected to it include advanced technology and a unique measurement method in which the sensors and the entire measurement configuration are located in the tip of the needle.

The electrodes on the tip release a small electric current to the tissue surrounding the tip. The device, which precisely measures the tissue’s electrical conductivity at several different frequencies, identifies when the tip of the needle is exactly at the right puncture point. The device then sends an audio alert to the physician.

The measurement device can also be used in clinical studies and in teaching situations to collect data generated by the needle, thus enabling the entire puncture procedure to be analyzed in retrospect.

The first application of Injeq’s smart needle to be commercialized was developed in collaboration with oncologists and pediatricians particularly for the treatment of childhood leukemia. During the treatment of leukemia, dozens of lumbar punctures (spinal taps) are performed on the patient in order to take cerebrospinal fluid samples and to inject chemotherapy drugs into the spinal canal to kill cancer cells.

Injeq’s smart needle is currently being tested on leukemia patients in three central university hospitals in Finland. The clinical study, which has already seen more than 140 punctures performed in clinical tests, has been proceeding well.

Medicine has advanced in leaps and bounds over the past 100 years, but the needles used for performing punctures have evolved very little during that time. Injeq is finally bringing needles and the safety of punctures into this millennium.

Injeq is participating in Congress of Joint European Neonatal Societies #jENS

Injeq is participating in Congress of Joint European Neonatal Societies #jENS. Our Chief Scientific Officer Dr. Harri Sievanen is presenting (poster 132). […]
Read more »

Injeq quality management system is now MDR 2017/745 and ISO 13485 certified

According to the Medical Device Regulation 2017/745 (MDR) all medical device manufacturers must have a Quality Management System. Injeq Oy […]
Read more »

Injeq Oy:n laatujärjestelmälle on myönnetty lääkinnällisten laitteiden luokan I ja IIa MDR sekä ISO 13485 -sertifikaatit

Lääkinnällisiä laitteita koskevan EU-asetuksen 2017/745 (Medical Device Regulation, MDR) mukaan kaikilla lääkinnällisten laitteiden valmistajilla on oltava laadunhallintajärjestelmä. Injeq Oy:lle on […]
Read more »

47th Annual Meeting of the Society for Neonatology and Paediatric Intensive Care (GNPI), 16 June 2021

Injeq IQ-Tip® system present at virtual 47th Annual Meeting of the Society for Neonatology and Paediatric Intensive Care (GNPI)
Read more »

Visit us at SIOP Europe 2021!

Stay up-to-date with the newest technology in performing the challenging lumbar punctures in pediatric leukemia patients. Take advantage of our […]
Read more »

2nd Annual Meeting of the European Society for Paediatric Oncology, 28 April 2021

Injeq IQ-Tip® system present at virtual SIOPE congress 28.-30. April 2021
Read more »